{"efta_number": "EFTA01964817", "page_count": 4, "url": "https://epstein-data.com/EFTA01964817", "pdf_url": "https://epstein-data.com/pdf/EFTA01964817.pdf", "pages": [{"efta_number": "EFTA01964817", "page_number": 0, "text_content": "A Financier Called Jeffrey Epstein Accelerates the Course of Evolution at Harvard\nEvolution is always on the move but nowhere has it been more in flux than at Harvard University.\nIndeed ten years ago, a brilliant Austrian biologist and mathematician called Martin Nowak,\ncollaborated with a then unknown New York financier called Jeffrey Epstein to establish the\nProgram for Evolutionary Dynamics. The financier's goal was not to give Harvard University a\n$30 million dollar gift to coddle neo-Darwinian theorists, but to accelerate key discoveries into\nthe evolution and treatment of major diseases from cancer to infectious bacteria and viruses such\nas HIV.\nIt all began in March of 2000 when Epstein, a New York fund manager with a passion for cutting-\nedge science, invited Nowak to organize a conference on the evolution of language. Nowak was\nthen head of the Program in Theoretical Biology at the Institute for Advanced Study at Princeton\nand had already published a substantial amount of work on the mathematics of the HIV virus,\ninfectious bacteria, and cancer cells. Before going to Princeton, Nowak had been the head of the\nmathematical-biology group at Oxford University.\nEpstein was no ordinary fund manager with a pension for science. By 2003, he was an established\nscience philanthropist. He had supported the research of many prominent scientists, including\nStephen Hawking, Marvin Minsky, Eric Lander, George Church, and Nobel laureate physicists\nGerard 't Hooft, David Gross, and Frank Wilczek. According to New York Magazine, he was one\nof the largest donors to individual scientists around the world, granting up to $200 million a year.\nHe was also a member of the New York Academy of Science, a member of Rockefeller\nUniversity's board, and actively involved in the Santa Fe Institute, the Quantum Gravity Program\nat the University of Pennsylvania, and the Mind, Brain & Behavior Advisory Committee at\nHarvard. Epstein himself had studied physics at the Cooper Union in New York and mathematics\nat the Courant Institute in New York and moved on to teaching calculus and physics at the Dalton\nSchool in Manhattan. Within a couple of years, he was quickly recruited into options trading on\nWall Street and applied his mathematical wit to the markets.\nBut Epstein's heart remained in the pure sciences. He was fascinated by fundamental questions on\nthe one hand and, on the other, eager to apply scientific theory to the real world. It was this\ncombination that drew him to Nowak. For Nowak's work embodied both large theoretical\nEFTA_R1_00441747\nEFTA01964817\n", "char_count": 2578}, {"efta_number": "EFTA01964817", "page_number": 1, "text_content": "concepts about evolution and also focused on the treatment of disease with the use of\nevolutionary mathematics. Not only could Epstein probe a brilliant mind about the origins of life,\nbut, with his connections at Harvard, was able to provide Nowak a powerful platform to put his\ngroundbreaking medical research into immediate practice.\nSo in August 2003, with the cooperation of Lawrence Summers, then president of Harvard, the\nProgram for Evolutionary Dynamics (PED) set up for business under the direction of Nowak,\nwho also became a professor of mathematics and biology at Harvard. In a few years, the PED\ntransformed the way in which evolution is studied and utilized. It became one of the first\nprograms to prioritize the use of mathematics in studying the evolution of microbiology and one\nof the first to develop a mathematical model of how human cancer cells evolve, as well as\ninfectious bacteria and viruses such as HIV.\nThe PED's models soon led to key discoveries towards combatting diseases of all kinds. In 2012,\nNowak and two postdoctoral students, Benjamin Allen and Ivana Bozic, developed the first\nmathematical model of how human colon-cancer cells evolve and how they become immune to\ninhibitor-drug therapy. Their research was conducted at the request of the Pathology and\nOncology Department at Johns Hopkins University. The department was trying to understand\nhow the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug therapy, making\nthe cells resistant to treatment.\nBy developing a mathematical model of the growth of colon-cancer cells, Nowak and his team\nshowed that the KRAS gene is not actually activated or \"switched on\" by inhibitor therapy;\nrather, a small percentage of colon-cancer cells with an already activated KRAS gene are immune\nfrom the start and come to dominate as the other cancer cells are destroyed by the inhibitor drug.\nThe discovery was critical in changing the approach to inhibitor-drug therapy. Instead of applying\ndrugs in sequence to fight secondary and tertiary resistance, the researchers at Johns Hopkins are\nnow exploring the effects of using a cocktail of inhibitor drugs to capture all colon-cancer cell\ntypes: those with the activated KRAS gene and those without. The same tailored approach is\nunderway for other cancers.\nIn 2010, Ivana Bozic and Martin Nowak co-authored a mathematical study that showed that most\nsolid tumors contain 40 to 100 genetic mutations, but that on average only 5 to 15 of those\nactually drive tumor growth. The findings were essential to the researchers at Johns Hopkins and\nEFTA_R1_00441748\nEFTA01964818\n", "char_count": 2616}, {"efta_number": "EFTA01964817", "page_number": 2, "text_content": "elsewhere because they demonstrated the importance of isolating a key minority of mutated tumor\ncells for effective inhibitor treatment.\n\"Mathematics in medical research reveals patterns that are otherwise hidden,\" remarked Epstein,\nwho maintains a frequent presence at PED. \"It's exhilarating when a mathematician can determine\nmolecular and cellular behavior with the precision of an engineer and share those findings with\nphysicians.\"\nIn that same year 2010, the PED presented to Bert Vogelstein, professor and director of the\nLudwig Center for Cancer Genetics and Therapeutics at the Johns Hopkins Kimmel Cancer\nCenter and the Howard Hughes Medical Institute, a mathematical model showing the genetic\nevolution of pancreatic-cancer cells from initial mutation to non-primary malignant cells. What\nNowak's team had found was surprising: that pancreatic cancer, one of the most lethal forms of\ncancer, is not fast and furious as believed, but slow to develop. In fact, given the amount and type\nof genetic disparity between the cellular stages, it appears that it takes about ten years for an\ninitiating mutation to grow to a parental, non-metastatic founder cell and another six years for\ncells to become malignant.\nThe findings highlighted the importance and real possibility of isolating pancreatic mutations prior\nto metastasis. Johns Hopkins scientists are now focusing on developing a pancreatic cancer\nscreening method similar to the protocol used for breast and colon cancers. Though early stages\nof pancreatic cancer cause no known symptoms, the John Hopkins team is looking into pancreatic\nscreening endoscopies for patients of a certain age.\nOver the last two years, Nowak and his team have also collaborated with the Johns Hopkins to\ndevelop a database to map and predict the effect of drugs on the HIV virus. Like cancer cells,\nHIV often develops resistance to drug cocktails. This is a major problem for patients and the trial\nand error of clinical trials can be hugely debilitating. Using data collected from thousands of blood\ntests on more than 20 anti-HIV drugs, the model calculates each drug's ability to suppress viral\nreplication and avoid resistant HIV strains. The model also factors in different drug combinations\nand dosages, and information about the patient such as blood type, age, and sex to arrive at the\nmost precisely engineered predictor of results for future patients.\nEFTA_R1_00441749\nEFTA01964819\n", "char_count": 2436}, {"efta_number": "EFTA01964817", "page_number": 3, "text_content": "Epstein's motivation for applied science differs from Nowak's. While Nowak is a practicing\nRoman Catholic and a declared humanist with a desire to serve society, Epstein is first and\nforemost a problem solver, interested in strategy and intellectual puzzles. He is equally devoted to\nphysics, artificial intelligence, and the human brain. According to Nowak, Epstein was fascinated\nwith his game theory of win-stay, lose-shift and eager to see how it could be applied to the\nmarkets. That is not to say that Epstein has no interest in purely humanistic endeavors. He has\ngiven to countless organizations to further early and primary education, notably in the U.S. Virgin\nIslands, where his foundation is based. But his essence is in uncovering the big questions, a\npossible but perhaps ultimately insatiable desire.\nMuch has been written about the Program for Evolutionary Dynamics and Martin Nowak's work.\nNowak is also the honored recipient of numerous awards, he is a frequent guest lecturer and the\nauthor of several books. And while Jeffrey Epstein remains an obscure figure, tarnished now by a\nseries of scandals involving underage women, one of which led to an 18-month jail sentence, he is\nnonetheless the talented catalyst, the accelerator of all this medical discovery. Whatever his\nignominy, Epstein's continued bond with Nowak and PED emphasizes that nature is not\nfastidious nor judgmental, nor is its dynamic always gradual. Discovery can be sparked into being\nby an unlikely source, pragmatically driven and above all, errs towards sustainability, no matter\nhow outlying its' gaze.\nEFTA_R1_00441750\nEFTA01964820\n", "char_count": 1627}]}